We are a global leader in the non-sterile liquid and semi-solid market. We’ve earned this position by forming an outstanding, experienced manufacturing team, investing in cutting edge equipment and facilities, prioritizing product quality, and keeping the customer top-of-mind at each and every stage of the process. We employ lean manufacturing principles, which our clients experience via reduced lead times.
Our facilities are registered with the U.S. FDA, Health Canada, and have been inspected by the Japanese Health Authority. There is also a Mutual Recognition Agreement between Canada and the European Union and Australia that allows products to be easily released to those regions.
Whether you’re starting from scratch with a brand-new product or trying to improve on an existing drug delivery system, CPL offers flexible filling and varied packaging solutions to meet your product requirements.
We are serialization-ready, in compliance with the Drug Quality Security Act (DQSA). Though compliance was not mandatory until November 2017, we have been ahead of the curve to ensure our products are traceable according to FDA standards. CPL can also support serialization for European markets that comply with the European Union Falsified Medicines Directive.
Additionally, we have invested in a serialization strategy of both software and hardware systems to support our partners’ serialization requirements with an ongoing strategy for aggregation as new traceability laws take effect.
Our GMP lab operations provide a complete range of testing services, from research and development to routine analytical testing, microbiological testing, and stability program management – all within our U.S. FDA and Health Canada approved establishments.